Top Stories: Sunday, May. 31

In Detail As of Sun, May 31, 2026, 21:07 pm, America/Chicago

RASolute 302 Trial at ASCO 2026 Plennary Session: Daraxonrasib Improves Survival Versus Chemotherapy in Previously Treated Metastatic PDAC

oncodaily - RASolute 302 Trial was presented by Brian M. Wolpin, MD, MPH, during the 2026 ASCO Annual Meeting.The Trial evaluated daraxonrasib, an oral RAS(ON) multi-selective inhibitor, against investigator’s choice chemotherapy in […]

AI Summary: A plenary ASCO presentation reports daraxonrasib, an oral KRAS G12C inhibitor, significantly improved overall survival compared with chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma. The data prompted immediate planning across cancer centers for anticipated demand and access changes — a rare dose of good news for a disease that usually gets none.

OPTIMA: Prosigna-Guided Chemotherapy Avoidance Shows Non-Inferior Outcomes in ER+/HER2− Early Breast Cancer

oncodaily - OPTIMA is one of the most important de-escalation studies presented at the 2026 ASCO Annual Meeting, because it addresses a daily clinical dilemma in early breast cancer: which patients truly […]

AI Summary: The OPTIMA trial demonstrated that using the Prosigna genomic test to select low‑risk ER+/HER2− early breast cancer patients allows omission of adjuvant chemotherapy without compromising disease control. The de‑escalation approach reduced exposure to chemo toxicity and supports molecular risk stratification to spare large numbers of patients unnecessary treatment — elegant, evidence‑based thrift.

Listen to the Latest ‘KFF Health News Minute’

kffhealthnews - The "KFF Health News Minute" brings original health care and health policy reporting from our newsroom to the airwaves each week.

AI Summary: A phase 2 study investigated FGFR inhibition with rogaratinib in succinate dehydrogenase–deficient gastrointestinal stromal tumors. Results reported tumor control in this rare molecular subset, offering a targeted therapeutic approach where options are sparse and validating FGFR as a biologic vulnerability in SDH‑deficient GIST.

American Cancer Society Updates Colorectal Cancer Screening Guideline: Major Changes Emphasize Blood-Based and At-Home Stool Testing

cancer - ACS researchers aim to reduce colorectal cancer deaths by offering options to improve screening participation

AI Summary: American Cancer Society revised colorectal screening guidelines, elevating at‑home stool testing and clarifying the role of blood‑based assays. Recommendations stress broader access to noninvasive stool tests while urging cautious, limited use of blood tests where appropriate, aiming to expand screening uptake without sacrificing diagnostic accuracy or overwhelming follow‑up resources.

Care navigation startup Garner Health banks $100M series E at $2.74B valuation

fiercehealthcare - The startup plans to use the capital to expand its provider quality platform, scale AI-powered product innovation and expand access.

AI Summary: Care navigation platform Garner Health closed a $100 million financing round to scale patient navigation and referrals to high‑performing clinicians, drawing strategic participation including Kaiser. The funding fuels expansion of tech‑enabled matchmaking between patients and clinicians while investors chase better outcomes and lower downstream costs.

Walmart, Teladoc Team Up to Expand Access to Virtual Care

Marissa Plescia / medcitynews - Through a new partnership, Teladoc Health’s virtual services are now available on Walmart’s Better Care Services platform.The post Walmart, Teladoc Team Up to Expand Access to Virtual Care appeared first on MedCity News.

AI Summary: Walmart has integrated Teladoc’s virtual care services into its digital health platform, rolling out expanded telemedicine access through its channels. The partnership merges Teladoc’s clinical offerings with Walmart’s scale to lower barriers to care, steer routine visits online, and extend convenient virtual options to price‑sensitive consumers — because waiting rooms are so last century.